o4

O4 is a novel stabilizer of amyloid- fibrils. O4 used for accelerating the formation of end-stage mature fibrils.

Bis[2-(1-isoquinolinyl-N)phenyl-C](2,4-pentanedionato-O2,O4)iridium(III) is a useful organic compound for research related to life sciences. The catalog number is T67275 and the CAS number is 435294-03-4.

ONO4057 is a potent and orally active Leukotriene B4 receptor antagonist with an IC50 value of 0.7±0.3 μM. Immunosuppressive effect of ONO4057 on rat allografts.

RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays

O4I1 is an effective Oct3/4 inducer.

CHBO4 is an hMAO-B inhibitor that is potent, reversible, competitive and selective.The IC50 value of CHBO4 against hMAO-B in the CHBO assay was 0.031 μM, and the Ki value was 0.010 ± 0.005 μM.CHBO4 reduces cellular damage by scavenging intracellular reactive oxygen species (ROS), and can be used to study Parkinson's disease (PD).

Ro4368554 is a selective 5-HT6 antagonist capable of crossing the blood-brain barrier. It can reverse memory deficits caused by scopolamine and tryptophan depletion. Ro4368554 is applicable for research related to memory impairments.

(E)-CHBO4 is an MAO-B inhibitor with an IC50 value of 0.023 μM, making it a potential candidate for research into Parkinson's disease treatment.

(R)-TCO4-PEG7-NH2 is a PROTAC linker classified under the PEG category. It includes a TCO group, which can undergo a specific "click" reaction with a tetrazine group.

(R)-TCO4-PEG2-NH2 is a PROTAC linker categorized under the PEG class. It contains a TCO group capable of undergoing a specific "click" reaction with tetrazine groups.

TCO4-PEG2-Maleimide, a PEG-based PROTAC linker, features TCO and Maleimide groups that enable specific "click" reactions with tetrazine groups or react with thiol groups through "thiol-ene" reactions.

TCO4-PEG2-Maleimide is a PROTAC linker classified under the PEG category. This compound features TCO and Maleimide groups, enabling it to participate in specific "click" reactions with tetrazine groups or "thiol-maleimide" reactions with thiol groups.

TCO4-PEG7-Maleimide is a PROTAC linker from the PEG class. This compound includes TCO and Maleimide groups, which can specifically engage in "click" reactions with tetrazine groups or in "thiol-maleimide" reactions with thiol groups.

TCO4-PEG3-Maleimide is a PROTAC linker of the PEG class. It contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, respectively, or participate in "thiol-Michael" addition.

TCO4-PEG3-Maleimide is a PROTAC linker from the PEG category. It incorporates TCO and Maleimide groups, which can selectively undergo "click" reactions with tetrazine groups or react with thiol groups through a "thiol-maleimide" reaction.

O4I2 is an effective Oct3/4 inducer in various human cell lines including human fibroblasts.

Ro4491533 is a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors (mGluR2/3).

RO4988546 is a potent negative allosteric modulator of mGlu₂/₃.

RO4987655 (RG7167) is an orally active and highly selective MEK inhibitor (IC50: 5.2 nM for MEK1/MEK2).

RO4929097 (RG-4733), a γ secretase inhibitor (IC50: 4 nM), inhibits cellular processing of Aβ40 and Notch (EC50: 14/5 nM).

TAK 438 xC4H4O4 is a useful organic compound for research related to life sciences and the catalog number is T66985.

RO4927350 is a potent and highly selective non-ATP-competitive MEK1/2 inhibitor. RO4927350 selectively blocks the MAPK pathway signaling both in vitro and in vivo, which results in significant antitumor efficacy in a broad spectrum of tumor models. RO4927350 inhibits not only ERK1/2 but also MEK1/2 phosphorylation. In cancer cells, high basal levels of phospho-MEK1/2 rather than phospho-ERK1/2 seem to correlate with greater sensitivity to RO4927350. Furthermore, RO4927350 prevents a feedback increase in MEK phosphorylation, which has been observed with other MEK inhibitors. RO4927350 represents a novel therapeutic modality in cancers with aberrant MAPK pathway activation.

RO4583298 is a highly potent dual NK1/NK3 receptor antagonist with in vivo activity.

PROTAC-O4I2, a PROTAC ligand targeting splicing factor 3B1 (SF3B1), induced FLAG-SF3B1 degradation in K562 cells with an IC50 value of 0.244 μM. PROTAC-O4I2 induced apoptosis in K562 WT cells.